Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.38 |
| ▸ | HTR2C | P28335 | 6/20 | 0.38 |
| ▸ | HTR2B | P41595 | 6/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 4/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5675555 | 1.00 | HTR2A (0.38) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| SCHEMBL5676899 | 1.00 | HTR2A (0.38) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| SCHEMBL1443833 | 1.00 | HTR2A (0.38) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| Succinic Acid SCHEMBL5676919 | 0.88 | HTR2C (0.36) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| Succinic Acid SCHEMBL5675653 | 0.88 | HTR2C (0.36) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| Fumaric Acid SCHEMBL5679289 | 0.88 | LMNA (0.42) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| Fumaric Acid SCHEMBL5679275 | 0.88 | LMNA (0.42) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| Fumaric Acid SCHEMBL5679256 | 0.88 | LMNA (0.42) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| Fumaric Acid SCHEMBL5679239 | 0.88 | LMNA (0.42) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| SCHEMBL8066004 | 0.85 | HTR2A (0.44) | HTR2AHTR2CHTR2BHRH3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2211871-A1 | METHOD FOR INHIBITING ANGIOGENESIS OR FOR TREATMENT OF CANCER | Faron Ventures OY (FI) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009056671-A1 | METHOD FOR INHIBITING ANGIOGENESIS OR FOR TREATMENT OF CANCER | FARON VENTURES OY (FI) | 2009-05-07 | — | — | WO | disclosed |
| EP-1414426-B1 | CARBOCYCLIC HYDRAZINO INHIBITORS OF COPPER-CONTAINING AMINE OXIDASES | BIOTIE THERAPIES CORP (FI) | 2006-03-01 | — | — | EP | disclosed |
| US-20040236108-A1 | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases | BIOTIE THERAPIES CORPORATION (FI) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236108-A1 | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases | AOC2, VCAM1, AOC3 | HTR2A 3923/4885HTR2C 3584/4885HTR2B 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.